Concenter BioPharma is currently raising funds for conducting this trial.

Concenter Biopharma granted approval for Phase 2a Clinical Trial at

Sheba Medical Center (Israel).


Prof. Mottie Chevion, CSO- Awarded FIRST PLACE
AWARDED FIRST PLACE

Zygosid-50 could be the first diabetes drug to restore near-normal cellular sensitivity to insulin, without side effects.

Concenter BioPharma is currently raising funds for conducting this trial. Concenter BioPharma's co-founder and CSO, Prof. Mottie (Mordechai) Chevion said: “the unique property of our drug candidate - Zygosid-50 is that it cancels out insulin resistance".









Hi, thanks for stopping by!

Concenter BioPharma is a subsidiary of Silkim Pharma Ltd., which developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications. 

 

Our PLATFORM is the result of extensive investigation of animal models of human diseases.

Let the news
come to you.

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter